


Clinical European Myeloma Network (EMN) guidelines to harmonize treatment selection for multiple myeloma



Multiple myeloma patients

Standard treatment



Autologous stem cell transplantation (ASCT)


Novel agents



Proteasome inhibitors, immunomodulatory drugs and monoclonal antibodies

Upfront autologous transplant

- Recommended sequential treatment for newly diagnosed MM patients eligible for high-dose chemotherapy and ASCT



- Factors to be considered for ASCT in newly diagnosed MM patients

Age (< or > 65 years)
Karnofsky performance status (< or > 90%)
Comorbidity (R-MCI score, HTCI) and organ function

Allogenic stem cell transplant

- In recent years → used as salvage strategy at relapse, often not in the context of clinical trials
- In future → used in combination with novel agents in the context of clinical trials for high-risk patients